Literature DB >> 28702814

Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.

Summer S Han1, S Ayca Erdogan2, Iakovos Toumazis3, Ann Leung4, Sylvia K Plevritis5.   

Abstract

BACKGROUND: The US preventive services task force (USPSTF) recently recommended that individuals aged 55-80 with heavy smoking history be annually screened by low-dose computed tomography (LDCT), thereby extending the stopping age from 74 to 80 compared to the national lung screening trial (NLST) entry criterion. This decision was made partly with model-based analyses from cancer intervention and surveillance modeling network (CISNET), which assumed perfect compliance to screening.
METHODS: As part of CISNET, we developed a microsimulation model for lung cancer (LC) screening and calibrated and validated it using data from NLST and the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO), respectively. We evaluated population-level outcomes of the lifetime screening program recommended by the USPSTF by varying screening compliance levels.
RESULTS: Validation using PLCO shows that our model reproduces observed PLCO outcomes, predicting 884 LC cases [Expected(E)/Observed(O) = 0.99; CI 0.92-1.06] and 563 LC deaths (E/O = 0.94 CI 0.87-1.03) in the screening arm that has an average compliance rate of 87.9% over four annual screening rounds. We predict that perfect compliance to the USPSTF recommendation saves 501 LC deaths per 100,000 persons in the 1950 U.S. birth cohort; however, assuming that compliance behaviors extrapolated and varied from PLCO reduces the number of LC deaths avoided to 258, 230, and 175 as the average compliance rate over 26 annual screening rounds changes from 100 to 46, 39, and 29%, respectively.
CONCLUSION: The implementation of the USPSTF recommendation is expected to contribute to a reduction in LC deaths, but the magnitude of the reduction will likely be heavily influenced by screening compliance.

Entities:  

Keywords:  CISNET; CT screening; Lung cancer; Microsimulation; NLST; Public health policy; USPSTF

Mesh:

Year:  2017        PMID: 28702814      PMCID: PMC5880208          DOI: 10.1007/s10552-017-0907-x

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  17 in total

1.  Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.

Authors:  Heber MacMahon; John H M Austin; Gordon Gamsu; Christian J Herold; James R Jett; David P Naidich; Edward F Patz; Stephen J Swensen
Journal:  Radiology       Date:  2005-11       Impact factor: 11.105

2.  Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers.

Authors:  Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Henry D Tazelaar; Jayawant N Mandrekar
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

3.  Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model.

Authors:  Rafael Meza; William D Hazelton; Graham A Colditz; Suresh H Moolgavkar
Journal:  Cancer Causes Control       Date:  2007-12-06       Impact factor: 2.506

4.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.

Authors:  B Rockhill; D Spiegelman; C Byrne; D J Hunter; G A Colditz
Journal:  J Natl Cancer Inst       Date:  2001-03-07       Impact factor: 13.506

5.  Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.

Authors:  Ray S Lin; Sylvia K Plevritis
Journal:  Cancer Causes Control       Date:  2011-11-25       Impact factor: 2.506

6.  The MISCAN-Fadia continuous tumor growth model for breast cancer.

Authors:  Sita Y G L Tan; Gerrit J van Oortmarssen; Harry J de Koning; Rob Boer; J Dik F Habbema
Journal:  J Natl Cancer Inst Monogr       Date:  2006

7.  Cost-effectiveness of computed tomography screening for lung cancer in the United States.

Authors:  Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

8.  Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Authors:  Rafael Meza; Kevin ten Haaf; Chung Yin Kong; Ayca Erdogan; William C Black; Martin C Tammemagi; Sung Eun Choi; Jihyoun Jeon; Summer S Han; Vidit Munshi; Joost van Rosmalen; Paul Pinsky; Pamela M McMahon; Harry J de Koning; Eric J Feuer; William D Hazelton; Sylvia K Plevritis
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

9.  Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control.

Authors:  Theodore R Holford; Lauren Clark
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

10.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

View more
  17 in total

1.  Disparities of National Lung Cancer Screening Guidelines in the US Population.

Authors:  Summer S Han; Eric Chow; Kevin Ten Haaf; Iakovos Toumazis; Pianpian Cao; Mehrad Bastani; Martin Tammemagi; Jihyoun Jeon; Eric J Feuer; Rafael Meza; Sylvia K Plevritis
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

2.  Re: Think before you leap.

Authors:  Summer S Han; Kevin Ten Haaf; William D Hazelton; Jihyoun Jeon; Rafael Meza; Chung Yin Kong; Eric J Feuer; Harry J de Koning; Sylvia K Plevritis
Journal:  Int J Cancer       Date:  2017-12-28       Impact factor: 7.396

3.  Adherence to Lung Cancer Screening: What Exactly Are We Talking About?

Authors:  Lori C Sakoda; Louise M Henderson; M Patricia Rivera
Journal:  Ann Am Thorac Soc       Date:  2021-12

4.  A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.

Authors:  Iakovos Toumazis; Oguzhan Alagoz; Ann Leung; Sylvia K Plevritis
Journal:  Cancer       Date:  2021-08-12       Impact factor: 6.860

5.  Predicting the Epidemiological Dynamics of Lung Cancer in Japan.

Authors:  Takayuki Yamaguchi; Hiroshi Nishiura
Journal:  J Clin Med       Date:  2019-03-08       Impact factor: 4.241

6.  Determinants Associated With Longitudinal Adherence to Annual Lung Cancer Screening: A Retrospective Analysis of Claims Data.

Authors:  Erin A Hirsch; Anna E Barón; Betsy Risendal; Jamie L Studts; Melissa L New; Stephen P Malkoski
Journal:  J Am Coll Radiol       Date:  2021-03-30       Impact factor: 6.240

7.  Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey.

Authors:  Rami A El Shafie; Dorothea Weber; Nina Bougatf; Tanja Sprave; Dieter Oetzel; Peter E Huber; Jürgen Debus; Nils H Nicolay
Journal:  JMIR Mhealth Uhealth       Date:  2018-08-30       Impact factor: 4.773

8.  Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

9.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

10.  Adherence to Follow-up Testing Recommendations in US Veterans Screened for Lung Cancer, 2015-2019.

Authors:  Eduardo R Núñez; Tanner J Caverly; Sanqian Zhang; Mark E Glickman; Shirley X Qian; Jacqueline H Boudreau; Christopher G Slatore; Donald R Miller; Renda Soylemez Wiener
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.